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PSA Bounce was seen in 7.2% of patients. Acute urinary retention 
rate was 4%. Mean Acute increase in IPSS scores was 6 points. 
There was no difference in acute GU toxicity between EBRT or 
brachytherapy boost doses. There was also no difference in acute 
toxicity if brachytherapy was done before or after EBRT. The rate 
of Late Grade 2+ GU toxicity was 13%. The rate of late Grade 2+ 
GI toxicity was 1.8%. 
Conclusions: This data shows excellent biochemical control 
comparable to most large series with HDR brachytherapy boost 
for prostate cancer. Toxicity was similar between dose regimens 
and further justifies moving towards hypofractionated regimens.  
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Purpose: Previous studies using T2-weighted (T2w) MRI showed 
significant uncertainties in brachytherapy target delineation, 
with conformity index for gross tumour volume at brachytherapy 
(GTVB) of 0.58-0.60. We examined the feasibility and utility of 
dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted 
MRI (DWI), and FDG PET imaging for brachytherapy target 
delineation in patients with locally advanced cervical cancer. 
Methods and Materials: Twenty-two patients with cervical 
squamous cell carcinoma or adenocarcinoma (12 Stage IB/IIA, 7 
IIB, 3 III/IVA) treated with definitive chemoradiation had DWI, 
DCE-MRI, and FDG PET/CT scan after brachytherapy applicator 
insertion, in addition to standard T2w MRI at 3T. GTVB and high-
risk clinical target volume (HRCTV) were contoured first on the 
axial T2w images by a single observer on the day of 
brachytherapy. The DWI, DWI-derived apparent diffusion 
coefficient map, DCE-MRI and FDG PET images were then 
reviewed, and if indicated the GTVB and/or HRCTV were 
modified to define the target more accurately, and/or include 
areas of suspected disease on DWI/DCE-MRI/FDG PET not obvious 
on T2w MR. Target delineation was performed by a second 
observer after brachytherapy treatment in the same manner. 
The primary endpoints were (1) feasibility; and (2) utility, 
determined by (a) the number of patients whose target volumes 
were modified based on DWI/DCE-MRI/FDG PET, and (b) 
interobserver variability using the conformity index (ratio 
between common and union volumes of a pair of contours by 
observers). 
Results: It was feasible to perform DWI, DCE-MRI and FDG PET 
without significantly delaying patients' brachytherapy 
treatment. The conformity indices for T2w-derived GTVB and 
HRCTV were 0.57 and 0.76, respectively. Eleven (50%) patients' 
T2w-GTVB contours were modified on the day of brachytherapy 
(Observer 1): seven based on better demarcation of the GTVB on 
DWI/DCE-MRI/FDG PET, and four based on DWI/DCE-MRI/FDG 
PET showing residual disease not well visualized on T2w MRI. 
GTVB was modified in 17 patients by Observer 2 (11 and six, 
respectively). Overall, Observer 1 found DWI, DCE-MRI and FDG 
PET useful for GTVB modification in nine, 11 and five patients, 
respectively; and in nine, 14 and eight patients respectively for 
Observer 2. For those patients, incorporation of functional 
imaging improved the conformity index for GTVB from 0.57 to 
0.66 (p < 0.001). HRCTV was modified in three and eight patients 
by Observers 1 and 2, respectively, with a trend towards higher 
conformity index using functional imaging (0.71 to 0.76, p = 
0.06). 
Conclusions: DWI, DCE-MRI and FDG PET imaging decreased 
interobserver variability in GTVB target delineation. Given data 
from retroEMBRACE showing the importance of minimum dose to 
the GTVB, reducing uncertainties in its delineation is of great 
importance. 
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Purpose: Over a multi-fraction course of intra-cavitary cervical 
brachytherapy (BT), treatment response will cause the HR-CTV 
to shrink. If BT is planned to conform to the HR-CTV, this change 
may impact dose to normal structures, having implications for BT 
scheduling and planning. 
Methods and Materials: Fifty patients receiving 26 Gy/4# or 
30Gy/5# intracavitary brachytherapy between January 1, 2014 
and December 31, 2015 as part of radical treatment for cervix or 
endometrial cancer were included in this study. Each fraction of 
BT was individually planned with the oncologist having available 
information from initial staging, EUA on day BT, intra-operative 
trans-abdominal u/s and CT-simulation. With a median time of 
27.1 days (range 9-43) between first and last implant, HR-CTV 
volume, point A dose and D2cc of bladder, rectum, sigmoid and 
small bowel were calculated for the first and last implant and 
compared using a paired t-test. 
Results: Between the first and last BT, HR-CTV volume shrank 
from a median of 23.7 cc to 15.5 cc (p = 0.001). This was 
associated with a reduction in median Point A dose from 520 cGy 
to 485.5 cGy (p = 0.002). Rectal, sigmoid and small bowel doses 
were not significantly different between the first implant and 
last with median D2cc of 221.5 versus 192.0 cGy (p = 0.9), 360.5 
versus 361.0 cGy (p = 0.3) and 173.0 versus 154.5 cGy (p = 0.9), 
respectively. However, median bladder D2cc dropped from 530.0 
to 486.0 cGy (p = 0.0003)  
Conclusions: Modest reductions in the size of the HR-CTV over 
the course of cervical BT are measurable and resulted in 
reductions in point A dose as well as bladder D2cc. These 
observations suggest that conforming BT to HR-CTV rather than 
point A and delivering BT after the cervix has been cytoreduced 
can potentially reduce bladder side effects. 
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Purpose: Cervical cancer remains to be a major health problem 
and cancer-related cause of death among women in developing 
countries such as Iran where the most cases are diagnosed in 
locally advanced stage. This cross sectional-analytic study aims 
to report outcome 154 patients with carcinoma of cervix were 
treated with external beam radiation therapy (EBRT) and high-
dose rate (HDR) brachytherapy with cobalt 60 (Co-6o) remote 
after loading system. 
Methods and Materials: A total of 154 patients with the 
international federation of gynecologist and oncologist (FIGO) 
Stages I-IVA with histopathologically confirmed carcinoma of 
cervix, followed by the radiation-oncology ward of Shohada-e-
Tajrish Hospital in Tehran, Iran, between February 2008 and 
March 2015. They were completed their scheduled EBRT and HDR 
brachytherapy with Co-60 remote after loading system. Out of 
this, 132 patients completed their standard follow up protocol. 
They were analyzed for three-year disease-free survival (DFS), 
three-year overall survival (OS) incidence of acute and late 
complications for HDR brachytherapy. 
Results: Fourteen patients (9.1 %) were in Stage I (FIGO 
classification), 8 (5.2%) were in Stage IIA, 26 (16.9%) were in 
Stage IIB, 100 (64.9%) were in Stage III, and 6 (3.9 %) were in 
Stage IVA. The follow up duration was between 6 - 60 months 
with a median of 38 months. Overall rectal and bladder 
treatment toxicity rates were 33.7%. The three-year DFS rate 
was 85.7%, 70.7 %, 41% and 16.6% for Stages I, II, III, IVA 
